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Abstract
We describe the prevalence of carriage and variables associated
with introduction of highly drug-resistant microorganisms
(HDRMO) into a French hospital via patients repatriated or recently
hospitalized in a foreign country. The prevalence of HDRMO was
11% (15/132), with nine carbapenamase-producing Enterobacteria-
ceae, nine carbapenem-resistant Acinetobacter baumannii and six
glycopeptide-resistant enterococci. Half of the admitted patients
(63/132, 48%) were colonized with extended spectrum beta-lac-
tamase-producing Enterobacteriaceae (ESBLPE). Among the four
episodes with secondary cases, three involved A. baumannii.
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Introduction
Hospitals are increasingly plagued by microorganisms highly
resistant to antimicrobials (HDRMO) [1,2]. These HDRMO
include carbapenamase-producing Enterobacteriaceae (CPE),
glycopeptide-resistant enterococci (GRE) and carbape-
nem-resistant Acinetobacter baumannii (CRAB). In France, the
prevalence of GRE, CP-Klebsiella pneumoniae and CRAB
isolated in 2012 from blood cultures was 0.8, 0.5% and 10–
20%, respectively [3,4].
Patients admitted after hospitalization in a country with a
high incidence of HDRMO are at strong risk of carrying
HDRMO and may serve as index cases for further transmis-
sion. In France, guidelines were issued to ﬁght against
HDRMO, including those imported from foreign countries
[5,6]. These guidelines are based on prompt identiﬁcation and
screening of patients hospitalized in a foreign country and
strict contact precautions pending results of admission
screening. The number of episodes (single case or outbreak)
of HDRMO, either GRE or CPE, in our hospital increased from
four to six per year in 2009–2011 to 17 in 2012. In 2012, 13
(76%) of these episodes involved patients repatriated or with a
history of a recent hospital stay in a foreign country.
We present a 15-month prospective surveillance of colo-
nization or infection with HDRMO in patients admitted to a
single French university hospital after a recent hospital stay in a
foreign country.
Methods
This study was performed at a 950-bed university hospital
providing both primary and tertiary care. From 10 July 2012 to
20 October 2013, we conducted a prospective survey of
patients repatriated (hospitalized for more than 24 h in foreign
hospitals, whatever the ward and the country) or hospitalized
in a foreign country within the last year, and admitted to our
hospital. For each possible case, demographic characteristics,
history of recent hospital stay, in-hospital data and microbi-
ological data were prospectively collected.
For extended spectrum beta-lactamase-producing Entero-
bacteriaceae (ESBLPE) and CPE, a rectal swab was plated on (i)
ChromID ESBL agar (Biomerieux, Marcy-l’Etoile, France) and
(ii) Drigalski agar (Biorad, Marne-la-Coquette, France) with an
imipenem and ertapenem e-test strip after overnight enrich-
ment with 0.5 mg/L of ertapenem [7]. For GRE, a rectal swab
was plated on Brillance VRE agar (Oxoid, Dardilly, France) after
overnight enrichment with broth supplemented with 6 mg/L
vancomycin (VRE broth, Biomerieux) or used for GenXpert
vanA-vanB PCR assay [8]. For methicillin-resistant staphylococ-
cal aureas (MRSA), a nasal swab was plated on ChromID MRSA
agar (Biomerieux). Strains were identiﬁed using mass spec-
trometry, and resistance was conﬁrmed with an antibiotic
susceptibility test (www.sfm-microbiologie.org). Genes of
carbapenemase, blaOXA-48, blaNDM, blaVIM, blaKPC and blaIMP
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were searched for by PCR in carbapenem-resistant Enterobac-
teriaceae and those for blaOXA-23 in CRAB [9].
Results
Overall, 132 patients were included and 15 (11%, 95%CI, 6–16)
were found to be colonized with HDRMO (Table 1). Among
the 15 patients with at least one highly drug-resistant
microorganism, eight, six and one patient were colonized
with one, two or three different HDRMO, respectively. In
total, 24 HDRMO were identiﬁed: nine were CPE, six
K. pneumoniae, one Escherichia coli, one Proteus rettgeri and
one Enterobacter cloacae, producing four OXA-48, two
NDM-1, two KPC and one IMP-2 carbapenemase. All six
GREs were E. faecium, ﬁve with vanA and one with vanB gene.
Eight of the nine CRAB produced a carbapenemase, six
OXA-23, one OXA-24 and one NDM.
Overall, 63 patients (48%; 95% CI, 40–56) were colonized
with at least onemultidrug-resistant microorganism (MDRMO),
ﬁve with MRSA and 60 with ESBLPE; two patients were
co-colonized with ESBLPE and MRSA. Twenty of the 60 patients
with ESBLPE were colonized with two different ESBLPE, with 80
ESBLPE overall, of which 47 (58%) were E. coli.
Patients with and without HDRMO did not differ according
to demographic characteristics (Table 2). The prevalence of
HDRMO was higher in patients repatriated from a foreign
country (n = 10/35; 28%) than in patients with a history of
hospitalization during the last year (n = 5/92; 5%). Most
patients originated from a North African country (n = 52;
39%), with no difference in HDRMO colonization according to
the visited region. The prevalence of HDRMO colonization
was higher in patients receiving antibiotics at admission to our
hospital (n = 11/54, 20%) than in patients without antibiotics
(n = 4/75, 5%) and in patients admitted to the ICU (n = 7/24,
29%) as compared with other units.
Among the 15 episodes of HDRMO, four were responsible
for secondary cases, three with CRAB (all in the medical ICU,
with 16 secondary cases) and one with GRE (a medical unit
with two secondary cases) (Table 1).
Discussion
We found a high prevalence of colonization with HDRMO in
patients with a recent history of a hospital stay abroad, with a
higher proportion in patients directly repatriated from a
foreign country.
The diversity of carbapenemases in patients with CPE is
likely to result from the different countries reported for the
hospital stay abroad. All patients with Enterobacteriaceae-pro-
ducing OXA-48 were admitted after a hospital stay in North
Africa, whereas others were from diverse regions, in accor-
dance with the world epidemiology of carbapenemases [1,10].
Five GREs were vanA E. faecium and one was vanB E. faecium
TABLE 1. Characteristics of patients carrying highly resistant microorganisms after a hospital stay abroad, Bichat - Claude
Bernard Hospital, 2012–2013
Gender, age Country Situation HDRMO MRB Secondary case(s)
M, 22 Morocco Repatriated Kp (OXA-48)
CRAB (OXA-23)
ESBL Kp No
F, 82 Morocco Repatriated Kp (OXA-48) ESBL Kp No
M, 74 Italy Repatriated GRE (van A)
Kp (KPC)
No No
M, 67 Algeria History of hospital
stay within 1 year
CRAB (NDM-1) ESBL Escherichia coli No




M, 67 Portugal Repatriated GRE (van A)
E. cloacae (IMP-2)
No No
M, 80 Ecuador History of hospital




F, 99 USA Repatriated GRE (van A) No No
M, 69 Algeria History of hospital
stay within 1 year
CRAB (OXA-23)
CRAB (OXA-24)
ESBL Kp 1 (CRAB)
F, 73 Morocco Repatriated Kp (OXA-48)
CRAB (OXA-23)
ESBL Kp 2 (CRAB)
M, 58 Kuwait History of hospital
stay within 1 year
CRAB (OXA-23) MRSA 13 (CRAB)
M, 40 Australia Repatriated GRE (van B) No No
M, 74 Tunisia Repatriated CRAB (OXA-23) No No
F, 55 Morocco History of hospital




M, 54 Mali Repatriated CRAB* ESBL Kp No
CRAB, carbapenem-resistant Acinetobacter baumannii; Kp, Klebsiella pneumoniae; GRE, glycopeptide-resistant enterococci; ESBL, extended-spectrum betalactamase-producing;
MRSA, methicillin-resistant Staphylococcus aureus; PCR, polymerase chain reaction.
*Non-identiﬁed genotype.
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in a patient repatriated from Australia, also according to GRE
epidemiology. Most CRAB produced OXA-23 carbapenemase
and originated from different regions, showing the wide
dissemination of this highly drug-resistant microorganism.
CRAB mainly involves units with a high workload, and frequent
use of invasive devices and antibiotics [11]. In our hospital, it
was responsible for three out four episodes with secondary
cases, suggesting a higher tendency to disseminate than CPE or
GRE.
Variables associated with a high prevalence of HDRMO (i.e.
repatriation, admission to our hospital with antibiotics and
admission to an ICU) suggested that patients with longer
exposure to the healthcare system in the country of origin
were at higher risk of acquiring HDRMO. The prevalence of
ESBLPE in patients with a history of recent hospital stay abroad
was high, which contrasts with the low prevalence of MRSA.
This high prevalence is likely to reﬂect strong exposure to
ESBLPE in most visited countries [12]. Our results are in line
with recent studies demonstrating a high acquisition rate of
ESBLPE after travelling abroad [13].
In conclusion, the prevalence of colonization with HDRMO
and MRMO is high in patients after a hospital stay abroad. This
should lead to systematic screening of these patients at
admission, especially in hospitals and countries that still have
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